CPDA-1 2.23 g/70mL (Anticoagulant Citrate Phosphate Dextrose Adenine SOLUTION) 2.23 g/70mL

CPDA-1 2.23 g/70mL is an anticoagulant solution used to preserve blood components. This intravenous solution contains citrate, phosphate, dextrose, and adenine, aiding in blood storage and compatibility.

Strength

2.23 g/70mL

Pack Size

70 mL in 1 BAG (0942-6316-01)

Manufacturer / TM Owner

Fenwal, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

CPDA-1 2.23 g/70mL is primarily used to preserve blood and its components during storage. This anticoagulant solution helps maintain the quality and viability of blood for transfusions. It is often used in medical settings where blood preservation is critical, such as in blood banks or during surgical procedures.

Side Effects

CPDA-1 2.23 g/70mL works by preventing blood from clotting, allowing it to be stored for longer periods. The solution contains components that help maintain the red blood cells' integrity and function. Common effects include the preservation of blood components, ensuring they remain viable for medical use.

Precautions & Warnings

CPDA-1 2.23 g/70mL should be handled with care to avoid contamination. It is important to follow proper storage guidelines to maintain its effectiveness. Always use sterile techniques when handling this solution to prevent infections or complications.

Avoid Interactions

CPDA-1 2.23 g/70mL may interact with certain medications or substances. It is important to consult with a healthcare provider before using this solution, especially if you are taking other medications. Always inform your healthcare provider about any allergies or sensitivities you may have.

Frequently Asked Questions

CPDA-1 2.23 g/70mL is used to preserve blood components during storage, ensuring they remain viable for transfusions.

This anticoagulant solution prevents blood from clotting, allowing it to be stored for longer periods while maintaining the integrity of blood components.

The primary effect is the preservation of blood components, ensuring they remain viable for medical use.

Handle with care to avoid contamination and follow proper storage guidelines to maintain effectiveness.

It may interact with certain medications, so consult a healthcare provider before use, especially if taking other medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.